CP0014753

CP0014753 is a highly potent and selective first-in-class antisense oligonucleotide developed by Contera Pharma for the treatment of Canavan disease, a severe genetic neurological disorder affecting young children. The drug is designed to modulate the expression of one of the genes involved in Canavan disease, with the therapeutic goal of reversing toxic accumulation of N-acetylaspartate (NAA) in the brain, thereby slowing or stopping disease progression. Currently, there are no approved treatments for Canavan disease. CP0014753 has demonstrated promising preclinical safety and efficacy data and is ready for IND-enabling studies[1].